Meeder Asset Management Inc. Purchases 7,483 Shares of Calithera Biosciences Inc (NASDAQ:CALA)

Meeder Asset Management Inc. increased its position in shares of Calithera Biosciences Inc (NASDAQ:CALA) by 769.9% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 8,455 shares of the biotechnology company’s stock after buying an additional 7,483 shares during the quarter. Meeder Asset Management Inc.’s holdings in Calithera Biosciences were worth $48,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Voya Investment Management LLC grew its stake in Calithera Biosciences by 12.4% in the third quarter. Voya Investment Management LLC now owns 18,324 shares of the biotechnology company’s stock valued at $57,000 after purchasing an additional 2,023 shares in the last quarter. Virtu Financial LLC bought a new position in Calithera Biosciences in the third quarter valued at approximately $95,000. Grimes & Company Inc. grew its stake in Calithera Biosciences by 24.6% in the fourth quarter. Grimes & Company Inc. now owns 25,300 shares of the biotechnology company’s stock valued at $144,000 after purchasing an additional 5,000 shares in the last quarter. Beddow Capital Management Inc. grew its stake in Calithera Biosciences by 144.4% in the fourth quarter. Beddow Capital Management Inc. now owns 27,500 shares of the biotechnology company’s stock valued at $157,000 after purchasing an additional 16,250 shares in the last quarter. Finally, California State Teachers Retirement System grew its stake in Calithera Biosciences by 43.5% in the third quarter. California State Teachers Retirement System now owns 73,521 shares of the biotechnology company’s stock valued at $227,000 after purchasing an additional 22,298 shares in the last quarter. Hedge funds and other institutional investors own 74.19% of the company’s stock.

A number of research analysts have weighed in on CALA shares. ValuEngine upgraded Calithera Biosciences from a “hold” rating to a “buy” rating in a research note on Tuesday, March 17th. SVB Leerink reaffirmed an “outperform” rating on shares of Calithera Biosciences in a research report on Wednesday, March 11th. BidaskClub cut Calithera Biosciences from a “buy” rating to a “hold” rating in a research report on Wednesday, March 11th. Finally, HC Wainwright began coverage on Calithera Biosciences in a research report on Wednesday, November 27th. They issued a “buy” rating and a $7.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Calithera Biosciences presently has an average rating of “Buy” and a consensus target price of $6.50.

NASDAQ:CALA traded up $0.25 during mid-day trading on Thursday, hitting $4.45. 48,829 shares of the stock were exchanged, compared to its average volume of 695,005. The stock has a market capitalization of $279.18 million, a price-to-earnings ratio of -2.27 and a beta of 2.15. The firm’s 50-day simple moving average is $5.92 and its 200 day simple moving average is $4.79. The company has a debt-to-equity ratio of 0.05, a quick ratio of 8.14 and a current ratio of 8.14. Calithera Biosciences Inc has a fifty-two week low of $2.45 and a fifty-two week high of $8.04.

Calithera Biosciences (NASDAQ:CALA) last released its quarterly earnings results on Wednesday, March 11th. The biotechnology company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.02). On average, analysts predict that Calithera Biosciences Inc will post -1.5 EPS for the current fiscal year.

Calithera Biosciences Company Profile

Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.

Recommended Story: What is a good dividend yield?

Want to see what other hedge funds are holding CALA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Calithera Biosciences Inc (NASDAQ:CALA).

Institutional Ownership by Quarter for Calithera Biosciences (NASDAQ:CALA)

Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.